ATE250571T1 - Kaliumkanal-blocker - Google Patents

Kaliumkanal-blocker

Info

Publication number
ATE250571T1
ATE250571T1 AT97934996T AT97934996T ATE250571T1 AT E250571 T1 ATE250571 T1 AT E250571T1 AT 97934996 T AT97934996 T AT 97934996T AT 97934996 T AT97934996 T AT 97934996T AT E250571 T1 ATE250571 T1 AT E250571T1
Authority
AT
Austria
Prior art keywords
potassium channel
channel blockers
treatment
cell proliferative
proliferative disorders
Prior art date
Application number
AT97934996T
Other languages
English (en)
Inventor
Neil Alexander Castle
Sean Patrick Hollinshead
Philip Floyd Hughes
Jose Serafin Mendoza
Joseph Wendell Wilson
George Amato
Serge Beaudoin
Michael Gross
Grant Mcnaughton-Smith
Original Assignee
Icagen Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc, Lilly Co Eli filed Critical Icagen Inc
Application granted granted Critical
Publication of ATE250571T1 publication Critical patent/ATE250571T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Heads (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Amplifiers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation By Low-Temperature Treatments (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Optical Communication System (AREA)
  • Pyridine Compounds (AREA)
AT97934996T 1996-07-26 1997-07-23 Kaliumkanal-blocker ATE250571T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2254796P 1996-07-26 1996-07-26
US08/893,160 US6083986A (en) 1996-07-26 1997-07-15 Potassium channel inhibitors
PCT/US1997/012559 WO1998004521A1 (en) 1996-07-26 1997-07-23 Potassium channel inhibitors

Publications (1)

Publication Number Publication Date
ATE250571T1 true ATE250571T1 (de) 2003-10-15

Family

ID=26696048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97934996T ATE250571T1 (de) 1996-07-26 1997-07-23 Kaliumkanal-blocker

Country Status (12)

Country Link
US (1) US6083986A (de)
EP (1) EP0923543B1 (de)
JP (1) JP2002513385A (de)
KR (1) KR20000029605A (de)
AT (1) ATE250571T1 (de)
AU (1) AU734711B2 (de)
BR (1) BR9710587A (de)
CA (1) CA2261814A1 (de)
DE (1) DE69725153T2 (de)
HU (1) HUP0003250A3 (de)
IL (1) IL128205A (de)
WO (1) WO1998004521A1 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510797A (ja) * 1997-07-22 2001-08-07 イーライ・リリー・アンド・カンパニー 医薬化合物
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
CO5090829A1 (es) * 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
WO2000012077A1 (en) * 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
DE19929076A1 (de) * 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
JP2003508512A (ja) * 1999-09-08 2003-03-04 ギルフォード ファーマシュウティカルズ インコーポレイテッド 非ペプチド性サイクロフィリン結合化合物とその用途
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
AU781365B2 (en) * 1999-12-21 2005-05-19 Icagen, Inc. Potassium channel inhibitors
ES2240420T3 (es) 2000-01-18 2005-10-16 Novartis Ag Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b.
US6566380B2 (en) * 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) * 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
WO2002040534A1 (en) * 2000-11-17 2002-05-23 Karolinska Innovations Ab Nucleotide and polypeptide sequences of kcna7, a mammalian voltage-gated potassium channel protein, and use thereof
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6849634B2 (en) * 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US10078087B2 (en) 2001-05-01 2018-09-18 Senomyx, Inc. Assays and enhancers of the human delta ENaC sodium channel
AU2002308481A1 (en) * 2001-05-01 2002-11-11 Senomyx, Inc. High throughput cell-based assay for monitoring sodium channel activity and discovery of salty taste modulating compounds
AU2002314132A1 (en) * 2001-05-31 2002-12-09 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New heterotetrameric potassium channels and uses thereof
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
CN1842709A (zh) 2003-07-10 2006-10-04 塞诺米克斯公司 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途
WO2005095349A1 (en) * 2004-04-01 2005-10-13 Pharmacia & Upjohn Company Llc Crystalline pyrazole derivative
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
US8565898B2 (en) * 2005-04-28 2013-10-22 Medtronic, Inc. Rate control during AF using cellular intervention to modulate AV node
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
CN101578259A (zh) * 2006-11-28 2009-11-11 威朗国际制药公司 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物
WO2009006611A1 (en) * 2007-07-03 2009-01-08 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
EP2527328A1 (de) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisochinoline, pharmazeutische Zusammensetzungen damit und deren therapeutische Verwendung
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
AU2010233694A1 (en) 2009-04-09 2011-09-29 Merck Sharp & Dohme B.V. Indane derivatives
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
US8846743B2 (en) * 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
CA2835835C (en) 2011-05-13 2019-04-02 Array Biopharma Inc. Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
NO3175985T3 (de) 2011-07-01 2018-04-28
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (zh) 2011-11-18 2014-08-27 艾伯维德国有限责任两合公司 N-取代的氨基苯并环庚烯、氨基四氢化萘、氨基茚满和苯烷基胺衍生物、包含所述衍生物的药物组合物及其在治疗中的用途
HK1201455A1 (en) 2012-01-27 2015-09-04 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2013130808A1 (en) 2012-02-29 2013-09-06 D.E. Shaw Research, Llc Methods for screening voltage gated proteins
WO2014078328A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
MX374242B (es) 2012-11-13 2025-03-05 Array Biopharma Inc Compuestos de n-pirrolidinil, n' -pirazolil-urea, tiourea, guanidina y cianoguanidina como inhibidores de trka cinasa.
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
RS55593B1 (sr) 2012-11-13 2017-06-30 Array Biopharma Inc Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola
WO2014078325A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
SG11201602935PA (en) 2013-10-17 2016-05-30 Abbvie Deutschland Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
MA40434B1 (fr) 2014-05-15 2019-09-30 Array Biopharma Inc 1-((3s,4r)-4-(3-fluorophényl)-1-(2-méthoxyéthyl)pyrrolidin-3-yl)-3-(4-méthyl-3-(2-méthylpyrimidin-5-yl)-1-phényl-1h-pyrazol-5-yl)urée comme inhibiteur de la kinase trka

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB536939A (en) * 1939-08-24 1941-06-03 Eastman Kodak Co Improvements in and relating to photographic colour development
IL62973A0 (en) * 1980-06-02 1981-07-31 Basf Ag Aralkylphenylureas,their manufacture and their use as herbicides
JPS60199862A (ja) * 1984-03-23 1985-10-09 Otsuka Pharmaceut Co Ltd インダン誘導体
GB8707123D0 (en) * 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5006512A (en) * 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
IL88314A (en) * 1987-11-18 1994-05-30 Tanabe Seiyaku Co Sulphonylamino indane derivatives, their preparation and pharmaceutical compositions containing them
DK691488A (da) * 1987-12-14 1989-06-15 Beecham Group Plc Hidtil ukendte forbindelser
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
US5215985A (en) * 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
DE69129611T2 (de) * 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
US5401848A (en) * 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5310932A (en) * 1991-04-15 1994-05-10 E. R. Squibb & Sons, Inc. Chromanyl substituted indole potassium channel openers
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5356775A (en) * 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5328830A (en) * 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) * 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
DE4302051A1 (de) * 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9309716D0 (en) * 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
DE69535315T2 (de) * 1994-01-10 2007-06-28 Teva Pharmaceutical Industries Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
FR2717805B1 (fr) * 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
US5615460A (en) * 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
ZA96211B (en) * 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
AU5772396A (en) * 1995-05-19 1996-11-29 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP0874625B1 (de) * 1996-01-22 2005-03-16 Eli Lilly And Company Indanderivate für antipsychotische mittel

Also Published As

Publication number Publication date
AU3803597A (en) 1998-02-20
HUP0003250A1 (hu) 2002-01-28
DE69725153D1 (de) 2003-10-30
IL128205A (en) 2003-09-17
IL128205A0 (en) 1999-11-30
HUP0003250A3 (en) 2002-02-28
BR9710587A (pt) 2000-10-31
EP0923543B1 (de) 2003-09-24
JP2002513385A (ja) 2002-05-08
HK1020334A1 (en) 2000-04-14
WO1998004521A1 (en) 1998-02-05
DE69725153T2 (de) 2004-06-09
CA2261814A1 (en) 1998-02-05
AU734711B2 (en) 2001-06-21
EP0923543A1 (de) 1999-06-23
KR20000029605A (ko) 2000-05-25
US6083986A (en) 2000-07-04

Similar Documents

Publication Publication Date Title
ATE250571T1 (de) Kaliumkanal-blocker
DE69916792D1 (de) Kaliumkanalblocker
ES2106965T3 (es) Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa.
AU5624699A (en) Use of 5ht-6 antagonists
ATE423557T1 (de) Carbocyclische kaliumkanalhemmer
EA199800667A1 (ru) Новые фенантридины
TR200003036T2 (tr) 12,13-Modifiye edilmiş epotilon türevleri
EA199700061A1 (ru) Способ получения силденафила
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
FI915093A0 (fi) Sackarinderivat anvaendbara som inhibitorer foer proteolytiskt enzym och deras framstaellning.
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
DE69727312D1 (de) 4-aryl-3-hydroxychinolin-2-on-derivate als modulatoren des ionenkanals
MXPA01010403A (es) Agentes quimiotacticos e inhibidores derivados de osteopontina y usos de los mismos.
IL129035A0 (en) 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
CA2227711A1 (en) Thioctic acid metabolites and methods of use thereof
NO990913L (no) Naftylforbindelser, intermediater, sammensetninger og metoder for anvendelse
BG100248A (bg) Инхибитори на скваленсинтетаза
ES2042726T3 (es) Beta-alquilmelatoninas.
DE3873278D1 (de) Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
IL139144A0 (en) Mycobacterial inhibitors
WO2002008183A3 (en) Potassium channel inhibitors
ES2160969T3 (es) Derivados anticonvulsivos utiles en el tratamiento de la psoriasis.
MX9203486A (es) (quinolin-2-imetoxi)indol como inhibidores de la biosintesis de leucotrienos).
ECSP961804A (es) Nuevos compuestos monociclicos de b -.lactama

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties